Asia FX muted despite Fed cut bets; Japanese yen slides after PM Ishiba resigns
Investing.com - H.C. Wainwright reiterated a Buy rating and $10.00 price target on Sangamo BioSciences (NASDAQ:SGMO), representing nearly 19x upside from the current price of $0.53, following the company’s presentation of full data from its Phase 1/2 STAAR study. According to InvestingPro data, the stock is currently trading 83% below its 52-week high of $3.18.
Sangamo presented detailed results for its gene therapy isaralgagene civaparvovec (isa-vec, ST’920) in Fabry disease at the International Congress of Inborn Errors of Metabolism 2025 in Kyoto, Japan on September 4.
The data showed a positive mean annualized estimated glomerular filtration rate (eGFR) slope, which measures improvement in renal function and has been accepted by the FDA as the primary basis for Accelerated Approval.
Sangamo plans to submit a biologics license application (BLA) for the therapy in the first quarter of 2026, according to the company’s announcement.
H.C. Wainwright stated that the full dataset "further de-risks isa-vec as a one-time, durable treatment with multi-organ benefit and a favorable safety profile," supporting its maintained Buy rating and $10 price target. The stock appears undervalued based on InvestingPro’s Fair Value model, with analyst targets ranging from $1.50 to $10.00.
In other recent news, Sangamo Therapeutics reported its Q2 2025 earnings, which fell short of expectations. The company posted an earnings per share (EPS) of -$0.08, missing the anticipated -$0.02. Revenue also came in below forecasts at $18.3 million, compared to the expected $29.9 million, marking a shortfall of 38.8%. In other developments, Sangamo announced promising data from its Phase 1/2 STAAR study of isaralgagene civaparvovec, a gene therapy for Fabry disease. The study showed positive kidney function outcomes with a mean annualized estimated glomerular filtration rate (eGFR) slope of 1.965 mL/min/1.73m²/year at 52 weeks. This positive kidney function was maintained at 104 weeks for patients with longer follow-up. These developments reflect the company’s ongoing efforts in gene therapy research despite recent financial challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.